The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Official Title: A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec Followed by Platinum-doublet Chemotherapy and Bevacizumab Compared With Physician's Choice of Chemotherapy and Bevacizumab in Women With Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Study ID: NCT05281471
Brief Summary: The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with Physician's Choice of chemotherapy and bevacizumab in women diagnosed with platinum-resistant/refractory ovarian cancer (includes fallopian tube cancer and primary peritoneal cancer). This Phase III trial builds on the efficacy and safety data reported in the previous Phase II VIRO-15 trial with promising objective response rate and progression-free survival observed in heavily pre-treated patients with platinum-resistant/refractory ovarian cancer. The phase II results also showed that the intra-peritoneal route of delivery was efficient in generating tumor cell killing and immune activation, and led to clinical reversal of platinum-resistance or refractoriness in this difficult-to-treat patient population.
Detailed Description: Olvi-Vec (olvimulogene nanivacirepvec, aka GL-ONC1, laboratory name: GLV-1h68) is an oncolytic vaccinia virus-based immunotherapy. This study is to test the hypothesis that the combination of Olvi-Vec followed by further chemotherapy is particularly effective against established tumors by virus-mediated immune activation and re-sensitization of tumor cells to chemotherapy. Participant population includes histologically confirmed non-resectable platinum-resistant/refractory ovarian cancer (PRROC). Determination of progression-free survival, safety and overall survival are key objectives. Participants randomized into the Experimental Arm will receive a single-cycle (2 infusions on two consecutive days) of Olvi-Vec through an intraperitoneal catheter. The catheter is then removed, and patients receive systemically administered platinum-doublet chemotherapy and bevacizumab. The control arm receives the Physician's Choice of chemotherapy and bevacizumab at the same dose and schedule. Biological samples will be obtained from some Experimental Arm participants for virus-shedding testing. Assessment of response to treatment in both arms will be by RECIST 1.1 and iRECIST as assessed by Blinded Independent Central Review. Maintenance/continued treatment with non-platinum chemotherapy and bevacizumab is dependent on a participant being clinically stable until confirmed progressive disease by iRECIST or can no longer tolerate therapy. Dr. Robert W. Holloway (AdventHealth Cancer Institute, Orlando, FL) will serve as the National Principal Investigator for this Phase 3 study in PRROC.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
The University of South Alabama, Mitchell Cancer Institute, Mobile, Alabama, United States
University of Arizona Cancer Center, Tucson, Arizona, United States
City of Hope, Duarte, California, United States
UC San Diego Health - Moores Cancer Center, La Jolla, California, United States
Hoag Gynecologic Oncology, Newport Beach, California, United States
UCI Health Chao Family Comprehensive Cancer Center, Orange, California, United States
AdventHealth Cancer Institute, Orlando, Florida, United States
Tampa General Hospital/University of South Florida, Tampa, Florida, United States
Women's Cancer Associates with Women's Care Florida, Tampa, Florida, United States
Indiana University Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States
Holy Cross Hospital, Silver Spring, Maryland, United States
Karmanos Cancer Institute, Detroit, Michigan, United States
Washington University School of Medicine, Saint Louis, Missouri, United States
Mercy Hospital St. Louis, Saint Louis, Missouri, United States
Center of Hope, Reno, Nevada, United States
Levine Cancer Institute, Charlotte, North Carolina, United States
Cleveland Clinic, Cleveland, Ohio, United States
Kettering Health, Kettering, Ohio, United States
Oklahoma University Health Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
AHN West Penn Hospital, Pittsburgh, Pennsylvania, United States
Hollings Cancer Center, Charleston, South Carolina, United States
Chattanooga's Program in Women's Oncology, Chattanooga, Tennessee, United States
Providence Sacred Heart Medical Center & Children's Hospital, Spokane, Washington, United States
Name: Robert W Holloway, MD
Affiliation: OnPrime Study
Role: PRINCIPAL_INVESTIGATOR